Clinical trialsCompany release

Corbus doses first patient in Phase 3 TEMPO-1 trial of Nectin-4 ADC sutantatug envedotin

🇺🇸 Corbus Pharmaceuticals Holdings, Inc. (CRBP) · Tue 10 Nov 2026

The US biotech also reported 5% mean weight loss at 12 weeks for oral obesity candidate CRB-913 and said cash should last into 2028.

Corbus Pharmaceuticals Holdings reported third-quarter 2026 results on 10 November, saying the first patient was dosed in September in TEMPO-1, a registrational Phase 3 study of sutantatug envedotin (CRB-701). The drug is a Nectin-4-targeting antibody-drug conjugate.

TEMPO-1 plans to enrol 250 patients with oropharyngeal cancer in the second-line or later setting. The study followed US Food and Drug Administration clearance in July.

The company also reported Phase 1b CANYON-1 data for CRB-913, an oral obesity candidate. Patients on the 60 mg dose achieved a mean weight loss of 5% at 12 weeks. Corbus intends to present the results at ObesityWeek on 15 November and to discuss development plans with the FDA.

On the financials, Corbus posted a net loss of $37.8 million for the quarter. It held $115.3 million in cash, which it expects to fund operations into 2028.

What it means for your team

  • Regulatory teams tracking Nectin-4 ADCs should note that a registrational study in head and neck cancer is now enrolling in the US, following FDA clearance in July.
  • The planned FDA discussions on CRB-913 mean the path from Phase 1b to later-stage development for this oral obesity candidate is not yet defined.
  • The 12-week, 5% mean weight loss figure comes from an early-stage study, so cross-programme comparisons should be made with caution.

Company's press release (SEC filing): Corbus Pharmaceuticals Holdings, Inc. ↗

Article written by VigiEye from the official source (Corbus Pharmaceuticals Holdings, Inc.). Claims are the company's own. AI-assisted; check the source before acting.

More Clinical trials All →